TY - JOUR
T1 - Treatments targeting inotropy
AU - Maack, Christoph
AU - Eschenhagen, Thomas
AU - Hamdani, Nazha
AU - Heinzel, Frank R.
AU - Lyon, Alexander R.
AU - Manstein, Dietmar J.
AU - Metzger, Joseph
AU - Papp, Zoltan
AU - Tocchetti, Carlo G.
AU - Yilmaz, M. Birhan
AU - Anker, Stefan D.
AU - Balligand, Jean-Luc
AU - Bauersachs, Johann
AU - Brutsaert, Dirk
AU - Carrier, Lucie
AU - Chlopicki, Stefan
AU - Cleland, John G.
AU - de Boer, Rudolf A.
AU - Dietl, Alexander
AU - Fischmeister, Rodolphe
AU - Harjola, Veli-Pekka
AU - Heymans, Stephane
AU - Hilfiker-Kleiner, Denise
AU - Holzmeister, Johannes
AU - de Keulenaer, Gilles
AU - Limongelli, Giuseppe
AU - Linke, Wolfgang A.
AU - Lund, Lars H.
AU - Masip, Josep
AU - Metra, Marco
AU - Mueller, Christian
AU - Pieske, Burkert
AU - Ponikowski, Piotr
AU - Ristic, Arsen
AU - Ruschitzka, Frank
AU - Seferovic, Petar M.
AU - Skouri, Hadi
AU - Zimmermann, Wolfram H.
AU - Mebazaa, Alexandre
N1 - Funding Information:
C.M. is supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 894, TRR-219, and Ma 2528/7-1), the German Federal Ministry of Education and Science (BMBF; 01EO1504) and the Corona foundation. J.M.M. is supported by grants from the NIH. C.G.T. is supported by grants of Federico II University-Ricerca d Ateneo. J.L.B. is supported by Fonds National de la Recherche Scientifique and European Union (UE Horizon2020 GA634559. A.D. is supported by the German Cardiac
Funding Information:
Society (DGK) and institutional research grants of the University Hospital Regensburg (ReForM-A/B). C.Mu. received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the European Union, the Cardiovascular Research Foundation Basel, Basel University and the University Hospital Basel. W.H.Z. is supported by the DZHK (German Center for Cardiovascular Research), the BMBF, the DFG (ZI 708/10-1, SFB 937 A18, SFB 1002 C04/01 and IRTG 1816 RP12), and Foundation Leducq.
Publisher Copyright:
© 2018 The Author(s).
PY - 2019/11/21
Y1 - 2019/11/21
N2 - Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesteraseinhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2þ. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation-contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.
AB - Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesteraseinhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2þ. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation-contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.
KW - Heart failure
KW - Acute decompensated heart failure
KW - Inotropes
KW - Cardiogenic shock
KW - Excitation-contraction coupling
KW - Calcium
KW - Sarcomeres
KW - Mitochondria
KW - Energetics
KW - Adrenergic receptors
KW - Contractility
KW - Levosimendan
KW - Omecamtiv mecarbil
KW - Nitroxyl
U2 - 10.1093/eurheartj/ehy600
DO - 10.1093/eurheartj/ehy600
M3 - Article
C2 - 30295807
SN - 0195-668X
VL - 40
SP - 3626
EP - 3644
JO - European Heart Journal
JF - European Heart Journal
IS - 44
ER -